Focus Partners Wealth Buys 15,048 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Focus Partners Wealth increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,736 shares of the biopharmaceutical company's stock after purchasing an additional 15,048 shares during the period. Focus Partners Wealth's holdings in Gilead Sciences were worth $10,875,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Ensign Peak Advisors Inc lifted its holdings in shares of Gilead Sciences by 3.8% during the 4th quarter. Ensign Peak Advisors Inc now owns 1,669,871 shares of the biopharmaceutical company's stock valued at $154,246,000 after purchasing an additional 60,474 shares in the last quarter. Ethic Inc. lifted its holdings in shares of Gilead Sciences by 7.9% during the 4th quarter. Ethic Inc. now owns 104,644 shares of the biopharmaceutical company's stock valued at $9,666,000 after purchasing an additional 7,638 shares in the last quarter. Fred Alger Management LLC lifted its holdings in shares of Gilead Sciences by 8.8% during the 4th quarter. Fred Alger Management LLC now owns 29,759 shares of the biopharmaceutical company's stock valued at $2,749,000 after purchasing an additional 2,402 shares in the last quarter. Colonial Trust Co SC lifted its holdings in shares of Gilead Sciences by 38.0% during the 4th quarter. Colonial Trust Co SC now owns 788 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 217 shares in the last quarter. Finally, CoreCap Advisors LLC lifted its holdings in shares of Gilead Sciences by 2,295.0% during the 4th quarter. CoreCap Advisors LLC now owns 24,668 shares of the biopharmaceutical company's stock valued at $2,279,000 after purchasing an additional 23,638 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

GILD traded up $2.16 during trading hours on Friday, reaching $102.50. The company's stock had a trading volume of 6,395,303 shares, compared to its average volume of 7,677,426. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company's 50-day moving average is $105.75 and its 200-day moving average is $99.84. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market cap of $127.50 billion, a PE ratio of 277.03, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the prior year, the business earned ($1.32) EPS. The firm's revenue for the quarter was down .3% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now directly owns 168,174 shares of the company's stock, valued at $17,893,713.60. This represents a 1.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 25,429 shares of company stock valued at $2,894,445 in the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

GILD has been the topic of several research reports. Piper Sandler boosted their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Bank of America boosted their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.